Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Post by Gtagalon Oct 14, 2021 7:05pm
207 Views
Post# 34007319

Insiders passing on info before disclosure to the public

Insiders passing on info before disclosure to the publicIt is so obvious that insiders have been passing on information to friends regarding soon to be released negative news.  On Tuesday  afternoon, the day before the press release of the financing of US$12M at $4.13 there was massive selling late in the afternoon when the stock market was up.  The next morning the stock plummeted on the news of dilution at a huge discount to the previous daystmarket price  Loyal Shareholders got screwed.

Likewise, this afternoon after 2:30PM  when the market was up big time, there was massive selling in the Canadian dollar shares, then after the close there was a lack lustre press release that we had all been waiting for since January.  After the press release tonight the US$ listied stock was up after market but then dropped 3% below  the days closing price.

This should be reported and investigated.  We are no playing with the big boys on the Nasdaq so more due diligence is required and moves like this will be scrutinized. Hope the Canadian market reacts positively in the moring to the news.



 

<< Previous
Bullboard Posts
Next >>